Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer

PURPOSE: Lapatinib, a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER-2/ErbB2), is effective against HER-2–positive locally advanced or metastatic breast cancer (MBC). This phase III trial evaluated the efficacy of lap...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Di Leo, Angelo, Gomez, Henry L., Aziz, Zeba, Zvirbule, Zanete, Bines, Jose, Arbushites, Michael C., Guerrera, Stephanie F., Koehler, Maria, Oliva, Cristina, Stein, Steven H., Williams, Lisa S., Dering, Judy, Finn, Richard S., Press, Michael F.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2008
Assuntos:
Breast Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2651098/
https://ncbi.nlm.nih.gov/pubmed/18955454
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.16.2578
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados